Investigational drug · Phase 3
B007
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "B007"
First trial start
2024
Jul 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pemphigus
- Primary Membranous Nephropathy
- Generalized Myasthenia Gravis
Approved drugs for the same conditions: Myasthenia gravis · Neurology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "B007" as an intervention, largest first.
- A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.Pivotal-lookingRecruiting
Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
NCT06470191 · 216 participants (planned) · Start Jul 30, 2024 · Primary completion Dec 31, 2026
Drug: B007; Cyclosporin Capsules · For: Primary Membranous Nephropathy
Sites: Beijing, China; Changchun, China; Guangzhou, China · 21 sites in all
- A Clinical Study of B007 in the Treatment of Pemphigus.Pivotal-lookingRecruiting
Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
NCT06454357 · 132 participants (planned) · Start Jul 12, 2024 · Primary completion Dec 31, 2026
Drug: B007 · For: Pemphigus
Sites: Beijing, China; Changsha, China; Chengdu, China · 12 sites in all
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.Pivotal-lookingRecruiting
Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
NCT06447597 · 104 participants (planned) · Start Jul 1, 2024 · Primary completion Dec 30, 2026
Drug: B007; Placebo · For: Generalized Myasthenia Gravis
Sites: Beijing, China; Changchun, China; Changsha, China · 18 sites in all
Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
NCT05668403 · 52 participants (planned) · Start Mar 2, 2023 · Primary completion Dec 30, 2026
Drug: B007; B007 and 1 more · For: Primary Membranous Nephropathy
Sites: Zhengzhou, China; Shijiazhuang, China; Hangzhou, China · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Design, synthesis, and biological evaluation of 1H-1,2,4-triazole-3-carboxamides as apelin receptor agonists.
Shen C, Zhou Y, Shen X, et al. · Bioorg Med Chem Lett 2026
- Fine mapping identifies CsGCN5 encoding a histone acetyltransferase as putative candidate gene for tendril-less1 mutation (td-1) in cucumber.
Chen F, Fu B, Pan Y, et al. · Theor Appl Genet 2017
- Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance.
Zucchetto A, Sonego P, Degan M, et al. · J Immunol Methods 2005
Also in development for Pemphigus
- TirabrutinibONO-4059Phase 33 trials
Ono Pharmaceutical Co., Ltd. · Pemphigus, Steroid-resistant Pemphigus, Relapsed/Refractory Primary Central Nervous System Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.